| Metric | Value ($ M) | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Revenue | 1.7K | 0.3% | 4.6% |
| Total Income | 1.7K | 0.3% | 4.6% |
| Expenditure | 1.6K | 0.7% | 31.4% |
| PBT | 98.00 | 20.7% | 114.2% |
| Net Profit | 203.40 | 433.9% | 128.6% |
| OPM | 8.21% | 1.02pp | 48.17pp |
| NPM | 11.98% | 9.73pp | 55.81pp |
| EPS | 0.30 | 400.0% | 128.8% |
Avantor Reports Q3 2026 Results, Exceeding Expectations and Raising FY26 Guidance
28 Oct 2026 · 28 Oct, 3:41 pm
Summary
Avantor, Inc. announced strong third quarter 2026 results, exceeding management's expectations for revenue and adjusted EPS. Net sales increased by 4.6% year-over-year to $1,698.3 million, driven by a 5.2% organic increase. The company reported a net income of $203.4 million, a substantial turnaround from the previous year's net loss. Management highlighted the return to year-over-year growth and raised full-year 2026 guidance for organic revenue growth, adjusted EPS, and free cash flow, signaling confidence in continued positive momentum.
Key Highlights
- 1
Avantor reported net sales of $1,698.3 million for the third quarter of 2026, an increase of 4.6% year-over-year, with organic growth of 5.2%.
- 2
The company's diluted GAAP EPS was $0.30, and adjusted EPS was $0.22 for Q3 2026.
- 3
Net income for the third quarter of 2026 was $203.4 million, a significant improvement from a net loss of $711.8 million in the prior-year period.
- 4
Adjusted EBITDA for the third quarter was $256.9 million, with an adjusted EBITDA margin of 15.1%.
- 5
The VWR Distribution & Services segment delivered organic growth of 5.8%, and Bioscience & Medtech Products returned to organic growth of 3.6%.
- 6
Avantor raised its fiscal year 2026 guidance for organic revenue growth, adjusted EPS, and free cash flow.
Management Comments
Emmanuel Ligner
We are delighted to return to year-over-year growth in the third quarter. We are not done with our Revival journey yet, but this achievement reflects the dedication of our associates and the progress we are making to sharpen our strategic focus and improve execution. Third quarter results exceeded our expectations across revenue and adjusted EPS, and we generated robust free cash flow that allowed us to further strengthen our balance sheet. VWR Distribution & Services delivered another quarter of improving revenue performance, with organic growth accelerating to 5.8%, and Bioscience & Medtech Products returned to organic growth as expected. We believe that improving execution and stronger end markets provide a foundation for sustained revenue growth, and we remain focused on execution to build on our positive momentum.
Informational and educational content only. Not investment advice.